The mechanisms of somatostatin induced enhanced chemosensitivity of gallbladder cancer cell line to doxorubicin: Cell cycle modulation plus target enzyme up-regulation

Biomedicine and Pharmacotherapy

Volumn 64, Issue 7, 2010, Pages 451-457

  Quan, Zhi Wei ^a   Yang, Yong ^a   Li, Ji Yu ^a   Gong, Wei ^a   Qin, Yi Yu ^a   Li, Song Gang ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cell cycle arrest; Doxorubicin; Gallbladder carcinoma; Regulation; Somatostatin; Topo II protein

Indexed keywords

CCAAT BINDING FACTOR; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEIN; PROTEIN ICBP90; RETINOBLASTOMA PROTEIN; SOMATOSTATIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DEATH; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME REGULATION; FLOW CYTOMETRY; GALLBLADDER CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; APOPTOSIS; CCAAT-BINDING FACTOR; CCAAT-ENHANCER-BINDING PROTEINS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG THERAPY, COMBINATION; E2F1 TRANSCRIPTION FACTOR; GALLBLADDER NEOPLASMS; HUMANS; RETINOBLASTOMA PROTEIN; SOMATOSTATIN; UP-REGULATION;

EID: 77956436169     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2010.01.010     Document Type: Article

References (41)

1. DeStoll M. Rationis Mendendi: in Nosocomio Practico vendobonensi. Part 1 Lugduni Batavarum, Haak et Socios et A. et J. Honkoop 1788.
2. Misra S., Chaturvedi A., Misra N.C., et al. Carcinoma of the gallbladder. Lancet Oncol 2003, 4(3):167-176.
3. Grobmyer S.R., Lieberman M.D., Daly J.M. Gallbladder cancer in the twentieth century: single institution's experience. World J Surg 2004, 28(1):47-49.
4. Qayyum A., Mujtaba I. Effcets of chemotherapy on patients with unresectable or metastatic adenocarcinoma of gallbladder. J Pak Med Assoc 2007, 57(2):71-74.
5. Teunissen J.J., Kwekkeboom D.J., Krenning E.P. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol 2004, 22(13):2724-2729.
6. Tejeda M., Gaal D., Hullan L., et al. A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models. Anticancer Res 2006, 26(4B):3011-3015.
7. Farinati F., Sergio A., Baldan A., et al. Octreotide and hepatocellular carcinoma. Br J Cancer 2007, 96(11):1778-1779.
8. Guillermet J., Saint-Laurent N., Rochaix P., et al. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci U S A 2003, 100(1):155-160.
9. Szepeshazi K., Schally A.V., Halmos G., et al. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. Cancer Res 2002, 62(3):781-788.
10. Ferjoux G., Bousquet C., Cordelier P., et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris 2000, 94(3-4):205-210.
11. Sharma K., Srikant C.B. Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 1998, 76(2):259-266.
12. Fueger B.J., Hamilton G., Raderer M., et al. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl Med 2001, 42(12):1856-1862.
13. Li J.Y., Quan Z.W., Zhang Q., et al. Effect of somatostatin on the cell cycle of human gallbladder cancer cell. J SSMU 2005, 17(1):57-60.
14. Li J.Y., Quan Z.W., Zhang Q., et al. The synergistic inhibitory effect of somatostatin-doxorubicin co-treatment on gallbladder carcinoma. BMC Cancer 2007, 7:125.
15. Chen G, Zeller W.J. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links. Anticancer Res 1991, 11(6):2231-2237.
16. Belpomme D., Gauthier S., Pujade-Lauraine E., et al. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol 2000, 11(11):1471-1476.
17. Litvak D.A., Bilchik A.J., Cabot M.C. Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: a novel treatment strategy. J Gastrointest Surg 2003, 7(1):140-148.
18. Ord J.J., Streeter E., Jones A., et al. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. Br J Cancer 2005, 92(12):2140-2147.
19. Shah T., Caplin M. Endocrine tumors of the gastrointestinal tract Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005, 19(4):617-636.
20. Gruszka A., Pawlikowski M., Kunert-Radek J. Antitumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: antiproliferative and pro-apoptotic effects. Neuro Endocrinol Lett 2001, 22(5):343-348.
21. Guillermet-Guibert J., Lahlou H., Cordelier P., et al. Physiology of somatostatin receptors. J Endocrinol Invest 2005, 28(11 Spl):5-9.
22. Hubina E., Nanzer A.M., Hanson M.R., et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 2006, 155(2):371-379.
23. Sharma K., Patel Y.C., Srikant C.B. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol Endocrinol 1999, 13(1):82-90.
24. Pagliacci M.C., Tognellini R., Grignani F., et al. Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analog SMS 201-995: effects on cell cycle parameters and apoptotic cell death. Endocrinology 1991, 129(5):2555-2562.
25. Massari D., Trobonjac Z., Rukavina D., et al. SMS 201-995 enhances S-phase block induced by 5-fluorouracil in a human colorectal cancer cell line. Anticancer Drugs 2005, 16(9):989-996.
26. Ling Y.H., el-Naggar A.K., Priebe W., et al. Cell cycle-dependent cytotoxicity G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 1996, 49(5):832-841.
27. Walker J.V., Nitiss J.L. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest 2002, 20(4):570-589.
28. Hsiang Y.H., Wu H.Y., Liu L.F. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 1988, 48(11):3230-3235.
29. McClendon A.K., Osheroff N. DNA topoisomerase II, genotoxicity, and cancer. Mutat Res 2007, 623(1-2):83-97.
30. Harris A.L., Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 1992, 31(2):205-213.
31. Zhou Z., Zwelling L.A., Kawakami Y., et al. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 1999, 59(18):4618-4624.
32. Arpino G., Ciocca D.R., Weiss H., et al. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 2005, 92(1):69-75.
33. Matsushime H., Ewen M.E., Strom D.K., et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 1992, 71(2):323-334.
34. Connell-Crowley L., Harper J.W., Goodrich D.W. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 1997, 8(2):287-301.
35. Nevins J.R., Leone G., DeGregori J., et al. Role of the Rb/E2F pathway in cell growth control. J Cell Physiol 1997, 173(2):233-236.
36. Hopfner R., Mousli M., Jeltsch J.M., et al. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression. Cancer Res 2000, 60(1):121-128.
37. Hopfner R., Mousli M., Garnier J.M., et al. Genomic structure and chromosomal mapping of the gene coding for ICBP90, a protein involved in the regulation of the topoisomerase II alpha gene expression. Gene 2001, 266(1-2):15-23.
38. Mousli M., Hopfner R., Abbady A.Q., et al. ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells. Br J Cancer 2003, 89(1):120-127.
39. Unoki M., Nishidate T., Nakamura Y. ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 2004, 23(46):7601-7610.
40. Trotzier M.A., Bronner C., Bathami K., et al. Phosphorylation of ICBP90 by protein kinase A enhances topoisomerase IIalpha expression. Biochem Biophys Res Commun 2004, 319(2):590-595.
41. Hopfner R., Mousli M., Oudet P., et al. Overexpression of ICBP90, a novel CCAAT-binding protein, overcomes cell contact inhibition by forcing topoisomerase II alpha expression. Anticancer Res 2002, 22(6A):3165-3170.